Analytical Data
-
Gene name
CPLX1
- Application
-
Alternative Names
CPLX1;Complexin-1
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O14810
-
Expression Region
1-134aa
-
AA Sequence
MEFVMKQALG GATKDMGKML GGDEEKDPDA AKKEEERQEA LRQAEEERKA KYAKMEAERE AVRQGIRDKY GIKKKEEREA EAQAAMEANS EGSLTRPKKA IPPGCGDEVE EEDESILDTV IKYLPGPLQD MLKK
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CPLX1 (Complexin 1) is a key protein involved in the regulation of neurotransmitter release at synapses, playing a crucial role in synaptic transmission and plasticity. It functions by binding to the SNARE complex, mediating vesicle fusion and the release of neurotransmitters, and ensuring the proper synchronization of neuronal communication. Dysregulation of CPLX1 has been implicated in various neurological disorders, including autism spectrum disorders and schizophrenia, highlighting its importance in maintaining synaptic health and functionality. Recent studies have focused on the characterization and production of recombinant CPLX1 proteins to elucidate its structure-function relationships, interactions with other synaptic proteins, and the molecular mechanisms underlying its role in neurotransmission. By utilizing recombinant DNA technology, researchers aim to produce CPLX1 in sufficient quantities for detailed biophysical and biochemical analysis, enabling the exploration of its effects on synaptic activity and potential therapeutics for synaptic dysfunction. Understanding CPLX1's precise functions and interactions at the molecular level could provide valuable insights into synaptic biology and pathophysiology, paving the way for novel treatments for related neurological conditions.
